Saving Access to Laboratory Services Act

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.

Client expense: $560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Proposals related to Medicare coverage of continuous glucose monitors. Proposals to ensure Medicare coverage for emerging medical device technology. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule.

Client expense: $1,080,000 · Firm income: Not reported

Government targets: Health & Human Services, Dept of (HHS), SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Proposals related to Medicare coverage of continuous glucose monitors. Proposals to ensure Medicare coverage for emerging medical device technology. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule.

Client expense: $1,060,000 · Firm income: Not reported

Government targets: Health & Human Services, Dept of (HHS), SENATE

VALID Act, FDA regulation of laboratory testing; Salsa Act H.R. 1835/ S 4449; pending proposed regulations for LDTs

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare, Medicaid, NIH Funding; Medical Education Funding; 340B; Drug Pricing; H.R. 3; Hospital Outpatient Reimbursement; FY 2022 Omnibus Appropriations; Extension of Telehealth COVID-19 rules - Telehealth; VALID Act; Salsa Act H.R. 1835; Pending FDA regulation of LDTs

Client expense: Not reported · Firm income: $65,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025- Issues related to funding government departments and agencies responsible for health care programs and support for a delay to certain cuts to laboratory payments covered by Medicare. Issues related to combatting the syphilis crisis in the United States and its impact on underserved communities. H.R. 4366 - Consolidated Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of 2024 - Issues related to funding of programs promulgated by the Department of Health and Human Services and its agencies, including CMS. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025- Issues related to funding government departments and agencies responsible for health care programs and support for a delay to certain cuts to laboratory payments covered by Medicare. Rules and regulations related to FDA's treatment of certain laboratory developed tests. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues. Issues related to testing for STDs. Issues related to testing for PFAS. Issues related to the Cancer Moonshot initiative and addressing ways to combat and prevent cancer.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R.1835 - Saving Access to Laboratory Services Act S.1000 - Saving Access to Laboratory Services Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. Proposals related to Medicare coverage of continuous glucose monitors. Proposals to ensure Medicare coverage for emerging medical device technology. Proposals related to medical device reimbursement and coverage.

Client expense: $1,050,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

VALID Act, FDA regulation of laboratory testing; Salsa Act H.R. 1835/ S 4449; pending proposed regulations for LDTs

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare, Medicaid, NIH Funding; Medical Education Funding; 340B; Drug Pricing; H.R. 3; Hospital Outpatient Reimbursement; FY 2022 Omnibus Appropriations; Extension of Telehealth COVID-19 rules - Telehealth; VALID Act; Salsa Act H.R. 1835; Pending FDA regulation of LDTs

Client expense: Not reported · Firm income: $63,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.

Client expense: $640,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $640,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H. R. 9747 - Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for health care programs and support for a delay to certain cuts to laboratory payments covered by Medicare. Issues related to combatting the syphilis crisis in the United States. Rules and regulations related to FDA's treatment of certain laboratory developed tests. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues. Issues related to testing for STDs. Issues related to testing for PFAS. Issues related to the Cancer Moonshot initiative and addressing ways to combat and prevent cancer.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H. R. 9747 - Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for health care programs and support for a delay to certain cuts to laboratory payments covered by Medicare. Issues related to combatting the syphilis crisis in the United States and its impact on underserved communities. H.R. 4366 - Consolidated Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of 2024 - Issues related to funding of programs promulgated by the Department of Health and Human Services and its agencies, including CMS. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to H.R.1835 - Saving Access to Laboratory Services Act H.R. 1691- Ensuring Patient Access to Critical Breakthrough Products Act

Client expense: Not reported · Firm income: Not reported

* On April 2, ADLM provided feedback to Senator Bill Cassidy (R-LA) on the need diagnostic testing reform.v * On April 8, ADLM provided survey results to Senator Bill Cassidy (R-LA) illustrating problems with the Food and Drug Administration's October 3, 2023 proposed rule to regulate laboratory developed tests. * On June 24, 2024 ADLM provided additional survey results to Senate HELP and House Energy & Commerce Committee leaders identifying concerns with the May 6, 2024 FDA final rule on LDTs. * ADLM met with House and Senate legislative staff in support of the Saving Access to Laboratory Services Act, H.R.1835 & S.1000, and conducted a grassroots campaign in support of the bill. *ADLM conducted a grassroots campaign in support of congressional action to revoke the May 6, 2024 FDA rule on LDTs.

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R.1835 - Saving Access to Laboratory Services Act S.1000 - Saving Access to Laboratory Services Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. Proposals related to Medicare coverage of continuous glucose monitors.

Client expense: $910,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare, Medicaid, NIH Funding; Medical Education Funding; 340B; Drug Pricing; H.R. 3; Hospital Outpatient Reimbursement; FY 2022 Omnibus Appropriations; Extension of Telehealth COVID-19 rules - Telehealths; VALID Act; Salsa Act H.R. 1835; Pending FDA regulation of LDTs

Client expense: Not reported · Firm income: $63,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

VALID Act, FDA regulation of laboratory testing; Salsa Act H.R. 1835/ S 4449; pending proposed regulations for LDTs

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.

Client expense: $650,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $650,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to combatting the syphilis crisis in the United States and its impact on underserved communities. H.R. 4366 - Consolidated Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of 2024 - Issues related to funding of programs promulgated by the Department of Health and Human Services and its agencies, including CMS. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to combatting the syphilis crisis in the United States. H.R. 4366 - Consolidated Appropriations Act and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of FY2024 - Issues related to the funding of the Department of Health and Human Services and its agencies. Rules and regulations related to FDA's treatment of certain laboratory developed tests. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues. Issues related to testing for STDs. Issues related to testing for PFAS. Issues related to the Cancer Moonshot initiative and addressing ways to combat and prevent cancer.

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R.1835 - Saving Access to Laboratory Services Act S.1000 - Saving Access to Laboratory Services Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. H.R.3674 Providing Relief and Stability for Medicare Patients Act of 2023. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. Proposals related to Medicare coverage of continuous glucose monitors. Proposals related to outpatient coverage of cardiovascular medical devices.

Client expense: $1,390,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare, Medicaid, NIH Funding; Medical Education Funding; 340B; Drug Pricing; H.R. 3; Hospital Outpatient Reimbursement; FY 2022 Omnibus Appropriations; Extension of Telehealth COVID-19 rules - Telehealths; VALID Act; Salsa Act H.R. 1835; Pending FDA regulation of LDTs

Client expense: Not reported · Firm income: $64,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

VALID Act, FDA regulation of laboratory testing; Salsa Act H.R. 1835/ S 4449; pending proposed regulations for LDTs

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.

Client expense: $1,580,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $1,580,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4366 - Consolidated Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of 2024 - Issues related to funding of programs promulgated by the Department of Health and Human Services and its agencies, including CMS. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 4366 - Consolidated Appropriations Act and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of FY2024 - Issues related to the funding of the Department of Health and Human Services and its agencies. Rules and regulations related to FDA's treatment of certain laboratory developed tests. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues. Issues related to testing for STDs. Issues related to testing for PFAS. Issues related to the Cancer Moonshot initiative and addressing ways to combat and prevent cancer.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R.1835 - Saving Access to Laboratory Services Act S.1000 - Saving Access to Laboratory Services Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. H.R.3674 Providing Relief and Stability for Medicare Patients Act of 2023. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. Proposals related to Medicare coverage of continuous glucose monitors. Proposals related to diagnostic testing coverage.

Client expense: $810,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $720,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.

Client expense: $720,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

diagnostics regulation Saving Access to Laboratory Services Act, S. 1000, H.R. 1835

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

diagnostics regulation Saving Access to Laboratory Services Act, S. 1000, H.R. 1835

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

H.R. 6363 - Further Continuing Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. Rules and regulations related to FDA's treatment of certain laboratory developed tests. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues. Issues related to the Cancer Moonshot initiative and addressing ways to combat and prevent cancer.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6363 - Further Continuing Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R.1835 - Saving Access to Laboratory Services Act S.1000 - Saving Access to Laboratory Services Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770: Equitable Community Access to Pharmacist Services Act ; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act

Client expense: $530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 1000/H.R. 1835 Saving Access to Laboratory Services Act. Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. Proposals related to Medicare coverage of continuous glucose monitors. Proposals related to diagnostic testing coverage. Proposals related to medical device reimbursement and coverage.

Client expense: $1,150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE